SOURCE: BIOLASE Technology, Inc.

July 09, 2008 06:00 ET

BIOLASE Launches New Waterlase® C100 All-Tissue Dental Laser System; Unveils Broadened Product Strategy

IRVINE, CA--(Marketwire - July 9, 2008) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today the global launch of its new Waterlase® C100 hard and soft tissue laser. Designed for the restorative general dentist, the Waterlase C100 provides clinical procedures including cavity preparation, early stage periodontal therapy and soft tissue procedures with more patient comfort compared to conventional instrumentation. Introduced as part of the Company's new and expanded product strategy, Waterlase C100 is priced to appeal to a broader cross section of the dental market. First customer deliveries are expected to begin before the end of this year's third quarter.

The Waterlase C100 is being launched today at the national sales meeting of the Company's exclusive North American distribution partner Henry Schein Dental, part of Melville, NY-based Henry Schein, Inc. (NASDAQ: HSIC). It will also be launched next week in Europe, as well as in other markets including Korea, Japan, Germany, Spain, Australia and New Zealand.

BIOLASE Chief Executive Officer Jake St. Philip noted that the Company has engaged in market research since he came to the Company in January and that the results of those studies indicate that a broader product offering that complements the flagship Waterlase MD™ in the all-tissue laser segment with multiple price points can increase the adoption rates across many segments of the dental market, especially among dentists who are just starting to build their practices.

"This introduction marks the launch of a new product strategy at BIOLASE," said St. Philip. "Our overall corporate mission is to transform the practice of dentistry and to make every dental practice a Waterlase Dentistry practice. Considering the broad range of clinical and cosmetic dental procedures made possible and more effective by our YSGG laser technology, offering a full range of products across the spectrum of price points should get us much closer to that goal."

The Waterlase C100 all-tissue laser combines industry-leading Waterlase YSGG technology with excellent reliability, clinician control, operating efficiency, and flexibility in tip and accessory selection. While it offers a narrower scope of applications than Waterlase MD, it provides for an advanced level of clinical results and patient comfort in a wide range of hard and soft tissue procedures.

St. Philip continued, "Our goal is to provide every dentist a laser product that addresses the needs of his or her dental practice over time. The Waterlase MD is ideal for anyone with a well-established and successful practice. And now, with the introduction of the Waterlase C100, all-tissue laser dentistry is affordable to an entire new generation of dentists and a wide range of practices that desire to provide their patients with the benefits of both hard and soft tissue laser procedures but have not been in a position to purchase our more feature-rich, high-end Waterlase MD."

The addition of the Waterlase C100 to the product family complements the market leading Waterlase MD all-tissue laser and the highly successful ezlase™ diode soft tissue laser and now gives BIOLASE a full range of Waterlase Dentistry solutions to meet the laser needs of almost every practice regardless of age, size or specialization.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (, the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, contact:
    David M. Mulder
    Chief Financial Officer
    BIOLASE Technology, Inc.

    Jill Bertotti
    Allen & Caron